IL6 and hereditary clear cell renal cell carcinoma: Sunitinib, a drug for the treatment of renal cell carcinoma, activates the NF-κB signaling pathway through the IRE1α/TRAF2/IKKβ axis of the ER stress response, enhancing the expression of IL-6, IL-8, and TNF-α.